Emmyon has a large and growing portfolio of 27 granted patents and many pending patents for compositions and/or uses of small molecules in major markets, with granted patent coverage for the next 13-16 years.
Our ursolic acid patent portfolio includes 13 granted patents in the US, Japan, Europe, Canada, China, Australia and Israel, as well as extensive additional filings around the world. Our granted patent coverage for ursolic acid extends to the year 2034 in the US and to the year 2031 in other countries.
Our tomatidine patent portfolio includes 12 granted patents in the US, Japan, Europe, China, Australia, Israel and Hong Kong, as well as extensive additional filings around the world. Our granted patent coverage for tomatidine extends to the year 2033 in the US and to the year 2032 in other countries.
We also have many other pending patents for compositions and/or uses of other small molecules that reduce muscle atrophy, obesity and diabetes.